Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 172 people in the crizotinib group and 171 people in the chemotherapy group — 343 participants in total. The trial was measuring how long people with a certain type of lung cancer went without their disease getting worse (called progression-free survival), as well as a number of other outcomes including overall survival, how many people's tumours shrank, how long those responses lasted, and how quickly a response was seen. The reported data shows that, for the main outcome, the crizotinib group had a median progression-free survival (meaning the point at which half the group had experienced disease progression or death) of 10.9 months, compared with 7.0 months in the chemotherapy group. For overall survival — how long people lived from the start of treatment — the chemotherapy group had a reported median of 47.5 months, while the figure for the crizotinib group was listed as "not available" in the data, meaning it was not reported in a way that can be described here. The reported probability of being alive at 12 months was 83.5% for the crizotinib group and 78.4% for the chemotherapy group; at 18 months those figures were 71.5% and 66.6% respectively. The reported data also shows that 74.4% of participants in the crizotinib group had their tumour shrink or disappear (a complete or partial response), compared with 45.0% in the chemotherapy group. Among those who did respond, the reported duration of that response was 49.0 weeks in the crizotinib group and 22.9 weeks in the chemotherapy group. The time from the start of the study until a response was first recorded was reported as 6.1 weeks for the crizotinib group and 12.1 weeks for the chemotherapy group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Lymphoma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of lung cancer (non-squamous cell carcinoma) that has spread or come back and cannot be treated with local treatments like surgery or radiation.
- Your cancer has tested positive for a specific gene change involving the ALK gene.
- You have not had any previous systemic treatment (such as chemotherapy) for your advanced or spread cancer; if you have cancer that has spread to the brain, it must have been treated and be stable, with no ongoing need for steroid medications.
- You are willing and able to attend scheduled visits, follow the treatment plan, complete lab tests, and fill out patient questionnaires, and you have signed a dated consent form agreeing to take part.
- You are 18 years of age or older (if you are in India, you must also be 65 years old or younger).
Who may not be able to join:
- You are currently taking part in another clinical trial that involves a treatment.
- You have previously had treatment that specifically targeted the ALK gene.
- You have had a heart attack, severe chest pain, heart bypass surgery, heart failure, stroke, or mini-stroke within the 3 months before starting the study (being on blood thinners is generally permitted).
- You have certain heart rhythm problems that are moderate or severe, uncontrolled irregular heartbeat (atrial fibrillation), or an abnormal heart electrical reading (QTc interval above 470 msec) (confirm with trial site).
- You are pregnant or breastfeeding.
- You are taking certain medications or eating foods that are known to strongly affect how the study drug is processed by the body (confirm with trial site which specific drugs or foods apply to you).
- You have a known HIV infection.
- You have a known lung condition involving scarring or inflammation of the lung tissue.
- You have other serious ongoing medical or mental health conditions, severe digestive problems (such as persistent diarrhea or ulcers), or significant abnormal lab results that the study doctor believes would make it unsafe for you to participate.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
10 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-Free Survival (PFS) Based on IRR
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.